Studies open for Enrollment

ABCSG 45

A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status


ABCSG 49 / POLAR

A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer Palbociclib for HR positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)


ABCSG 50 / BRCA-P

A randomized, double-blind, placebo-controlled, multi-center, international phase 3 study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation.


ABCSG 53 / TAXIS / SAKK 23/16

A multicenter randomized phase III trial to compare tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer


ABCSG 55N /AMBHER

Description of patients with HER2 positive breast cancer undergoing neoadjuvant treatment and development of a dynamic composite risk score to predict the risk of distant recurrence


ABCSG 56 / SASCIA

Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment


ABCSG 57 / ALPHABET

A randomized phase III trial of trastuzumab + alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ advanced breast cancer


ABCSG 60 / CAMBRIA-1

A phase III, open-label, randomized study to assess the efficacy and safety of extended therapy with camizestrant versus standard endocrine therapy in patients with ER+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed at least 2 years of standard adjuvant endocrine-based therapy without disease recurrence.  


ABCSG C08 / EXERCISE

Randomized phase-III-trial of endurance exercise following adjuvant chemotherapy in colorectal cancer.




Share on


Top